UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number: 0-25844 TAITRON COMPONENTS INCORPORATED (Exact name of registrant as specified in its charter) | California | 95-424 ...

Financial Performance - Total revenue for Q3 2025 was $2,305,000, a 2.1% increase from $2,257,000 in Q3 2024[10] - Gross profit for Q3 2025 was $1,383,000, compared to $1,355,000 in Q3 2024, reflecting a gross margin improvement[10] - Net loss for Q3 2025 was $4,892,000, compared to a net loss of $3,547,000 in Q3 2024, representing an increase in losses[10] - For the nine months ended September 30, 2025, the company reported a net loss of $9,411,000, an improvement from a net loss of $11,706,000 for the same period in 2024, representing a 19.7% reduction in losses[14] - Product revenue for the three months ended September 30, 2025, was $2,305,000, a 2% increase from $2,257,000 in the same period in 2024[190] - Product revenue for the nine months ended September 30, 2025, was $6,988,000, a 2% increase from $6,833,000 in 2024[202]. Expenses and Cost Management - Operating expenses for Q3 2025 totaled $2,962,000, down from $5,099,000 in Q3 2024, indicating a significant reduction in costs[10] - Research and development expenses for Q3 2025 were $739,000, down from $908,000 in Q3 2024, indicating a focus on cost management[10] - Personnel costs for the three months ended September 30, 2025, were $1,635,000, down from $3,294,000 in the same period of 2024, showing a reduction of 50.5%[32] - Sales and marketing expenses for the three months ended September 30, 2025, decreased by $1,460,000, or 68%, compared to the same period in 2024[196]. - General and administrative expenses for the three months ended September 30, 2025, decreased by $508,000, or 25%, compared to the same period in 2024[197]. Cash and Assets - Cash and cash equivalents increased to $3,809,000 as of September 30, 2025, up from $1,769,000 at December 31, 2024[9] - Total assets rose to $7,296,000 as of September 30, 2025, compared to $5,491,000 at December 31, 2024[9] - Total liabilities increased to $11,640,000 as of September 30, 2025, up from $8,054,000 at December 31, 2024[9] - The accumulated deficit increased to $540,808,000 as of September 30, 2025, compared to $531,397,000 at December 31, 2024[9] Shareholder and Capital Management - The company issued 6,550,000 shares under a private placement offering, raising approximately $2,815,000 net of issuance costs[12] - The company plans to raise capital through equity offerings and may experience significant dilution for existing shareholders[20] - The company has outstanding warrants that may be exercised, although there is no assurance that they will be[19] Market and Product Development - The company’s operations are focused on developing and commercializing diagnostic tests for gynecologic disease, including the Ova1Plus workflow and OvaWatch[17] - The company plans to broaden its commercial focus from ovarian cancer to include differential diagnosis of other gynecological diseases, which is expected to enhance market opportunities[154] - The addressable market for the company's tests is projected to increase to between 2 and 4 million tests per year following the successful expansion of the OvaWatch test features[166] - The ENDOinform program aims to develop a multi-marker test for diagnosing endometriosis, targeting a market of over 6.5 million women in the U.S.[165] Operational Highlights - The number of OvaSuite tests performed decreased by 5% to 5,727 during the three months ended September 30, 2025, compared to 6,001 tests in the same period in 2024[191] - The company rebalanced its salesforce, resulting in a 167% increase in sales per full-time equivalent salesperson in Q3 2025 compared to Q3 2024[180] - OvaWatch was approved for sale in New York State, expanding the distribution agreement with BioReference to include this product[169] Regulatory and Compliance - The company’s common stock was delisted from Nasdaq on April 15, 2025, due to failure to meet the minimum stockholders' equity requirement[22] - The company has applied for an LCD for OvaWatch, which is currently under review, to enhance reimbursement coverage[173] Future Outlook - The company expects to continue incurring net losses and negative cash flows from operations for the remainder of 2025[18] - The company is evaluating the potential impact of ASU 2023-09, which addresses income tax disclosures, effective for fiscal years beginning after December 15, 2024[43]

Financial Performance - For Q3 2025, Verde Clean Fuels, Inc. reported a net loss of $2.3 million, with a diluted net loss per share of $0.06[4] - The total operating loss for the nine months ended September 30, 2025, was $9.3 million, compared to $8.8 million for the same period in 2024, reflecting an increase of approximately 5.7%[10] - The company recorded general and administrative expenses of $2.8 million for Q3 2025, compared to $2.7 million in Q3 2024, indicating a slight increase[10] - Research and development expenses for the nine months ended September 30, 2025, were $457,000, up from $350,000 in the same period of 2024[10] - The accumulated deficit as of September 30, 2025, was $30.9 million, compared to $27.3 million at the end of 2024[12] Assets and Cash Position - As of September 30, 2025, the company had cash and cash equivalents of $59.4 million and no debt, representing a significant increase from $19.0 million at the end of 2024[5] - Total assets as of September 30, 2025, were $67.2 million, a significant increase from $23.6 million at the end of 2024[12] Project Development - Construction in progress for the Permian Basin project amounted to $3.3 million, which includes $9.3 million in capitalized development costs[5] - Verde is advancing front-end engineering and design for a proposed natural gas-to-gasoline plant in the Permian Basin, in collaboration with Cottonmouth, a subsidiary of Diamondback[3] Strategic Focus - The company is focused on converting associated natural gas into gasoline, which is expected to provide a market for such natural gas while reducing carbon intensity[6]

Financial Performance - For Q3 2025, Verde Clean Fuels, Inc. reported a net loss of $2.3 million, with a diluted net loss per share of $0.06[4] - The total operating loss for the nine months ended September 30, 2025, was $9.3 million, compared to $8.8 million for the same period in 2024, reflecting an increase of approximately 5.7%[10] - The company recorded general and administrative expenses of $2.8 million for Q3 2025, slightly up from $2.7 million in Q3 2024[10] - Research and development expenses for the nine months ended September 30, 2025, totaled $457,000, compared to $350,000 for the same period in 2024, indicating a 30.6% increase[10] - The accumulated deficit as of September 30, 2025, was $30.9 million, up from $27.3 million at the end of 2024[12] Cash and Assets - As of September 30, 2025, the company had cash and cash equivalents of $59.4 million and no debt, representing a significant increase from $19.0 million at the end of 2024[5] - Total assets as of September 30, 2025, were $67.2 million, a substantial increase from $23.6 million at the end of 2024[12] Project Development - Construction in progress for the Permian Basin project amounted to $3.3 million, which includes $9.3 million of capitalized development costs[5] - Verde is advancing front-end engineering and design for a proposed natural gas-to-gasoline plant in the Permian Basin, in collaboration with Cottonmouth, a subsidiary of Diamondback[3] Strategic Goals - The company aims to deploy its proprietary liquid fuels processing technology to convert associated natural gas into gasoline, targeting lower carbon intensity compared to conventional gasoline[6]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 75201 (Zip Code) (855) 427-7360 (Registrant's telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: For the transition period from to Commis ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number: 001-42195 OS THERAPIES INCOPORATED (Exact name of registrant as specified in its charter) (State or othe ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Cayman Islands 98-1834924 (State or other jurisdiction of incorporation or organization) 401 S County Road #2588 Palm Beach, Florida 33480 (Address of ...

(Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-42610 NEW PROVIDENCE ACQUISITION CORP. III (Exact name of registrant as specified in its charter) Cayman Islands 98-1834924 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-42624 REPUBLIC DIGITAL ACQUISITION COMPANY FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 (Exact name of registrant as specified in its charter) Cayman Islands 98-1834128 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-42624 REPUBLIC DIGITAL ACQUISITION COMPANY (Exact name of registrant as specified in its charter) Cayman Islands 98-1834128 ...